Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,704.00+4.80%ETH$2,426.56+7.03%GOLD$4,092.80+0.49%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
EQ

NASDAQ · EQ

Equillium, Inc. Common Stock

Healthcare · Biotechnology

$1.41

Down-$0.01 (-0.71%)

Updated Nov 5, 2026, 12:05 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
47.6M
P/E ratio
-3.58
Dividend yield
0.00%
52-week range
$0.76 – $3.54
Volume
199.21K
Avg. volume
570.19K

Price performance · EQ

EQ price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

EQ closed at $1.41 after 20 trading sessions, up 1.44% for the selected period.

Last close
$1.41
Period change
+1.44%
Period low
$1.19
Period high
$1.50
Daily close
View OHLC price history
EQ OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.38$1.455$1.36$1.41199.21K
Nov 2, 2026$1.38$1.43$1.31$1.38337.7K
Oct 30, 2026$1.38$1.42$1.29$1.37310.72K
Oct 29, 2026$1.39$1.48$1.39$1.42299.93K
Oct 28, 2026$1.40$1.43$1.36$1.42227.35K
Oct 27, 2026$1.26$1.39$1.23$1.36345.67K
Oct 26, 2026$1.20$1.25$1.17$1.25210.79K
Oct 23, 2026$1.25$1.2935$1.18$1.23315.66K
Oct 22, 2026$1.40$1.4199$1.23$1.27315.47K
Oct 21, 2026$1.40$1.51$1.385$1.42442.54K
Oct 20, 2026$1.25$1.43$1.24$1.38774.54K
Oct 19, 2026$1.22$1.2907$1.16$1.243.19M
Oct 16, 2026$1.32$1.35$1.185$1.19466.79K
Oct 15, 2026$1.30$1.38$1.28$1.32510.93K
Oct 14, 2026$1.32$1.38$1.30$1.30263.78K
Oct 13, 2026$1.50$1.50$1.32$1.32397.77K
Oct 12, 2026$1.42$1.51$1.39$1.50383.75K
Oct 9, 2026$1.45$1.46$1.38$1.41522K
Oct 8, 2026$1.41$1.46$1.34$1.44645.03K
Oct 7, 2026$1.41$1.425$1.35$1.39343.32K

Latest EQ news

The latest Smart Investors Daily articles mentioning EQ.

Stock researchCompany · Overview

EQ research

Overview

Company profile and research snapshot.

Company profile

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.00
Implied upside
—
Analysts
—
EQ recent ratings
DateFirmRatingTarget
Sep 4, 2026Roth CapitalBuy—
Jul 13, 2026Piper SandlerOverweight—
Jun 2, 2026Roth CapitalBuy—
May 28, 2026Roth CapitalBuy—
May 28, 2026Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504

Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of $20 million in additional funding under previously announced equity private placement agreement; cash expected to fund currently planned operations into 2029 LA JOLLA, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat

Yahoo · Oct 6, 2026

Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference

New preclinical data further characterizes EQ504’s coordinated effects across epithelial and immune compartments in intestinal inflammationLA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in a poster at the 50th Anniversary La Jolla Immunology Conference, taking place October

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By